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Highlights 
 Epigenetic discrimination of 10 monozygotic twin pairs was investigated under the 
forensic scenario.  
 Genome-wide methylation array analysis in blood reference DNA identified numerous 
candidate markers. 
 Top 3 markers were validated using methylation-specific qPCR and tested in trace DNA. 
 67.85% and 68.5% of markers showed >0.1 twin differences in reference and trace DNA, 
respectively. 
 A proportion of twin-differentiating markers in reference DNA may be non-informative 
in trace DNA. 
 
Abstract 
Monozygotic (MZ) twins share the same STR profile, demonstrating a practical problem in 
forensic casework. DNA methylation has provided a suitable resource for MZ twin differentiation; 
however, studies addressing the forensic feasibility are lacking. Here, we investigated epigenetic 
MZ twin differentiation from blood under the forensic scenario comprising i) the discovery of 
candidate markers in reference-type blood DNA via genome-wide analysis, ii) the technical 
validation of candidate markers in reference-type blood DNA using a suitable targeted method, 
and iii) the analysis of the validated markers in trace-type DNA. Genome-wide methylation 
analysis in blood DNA from 10 MZ twin pairs resulted in 19 to 111 twin-differentially methylated 
sites (tDMSs) per pair with >0.3 twin-to-twin differences. Considering all top three candidate 
tDMSs across all pairs in the technical validation based on methylation-specific qPCR, 67.85% 
generated >0.1 twin-to-twin differences. Of the validated tDMSs, 68.4% showed >0.1 twin-to-
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twin differences with qPCR in trace-type DNA across 8 pairs. Using an updated marker selection 
strategy, 8 additional candidate tDMSs were obtained for an example MZ pair, of which 7 showed 
>0.1 twin-to-twin differences in both reference- and trace-type DNA. Lastly, we introduce a high-
resolution melting curve analysis of the entire fragment that can complement the proposed 
approach. Overall, our study demonstrates the general feasibility of epigenetic twin differentiation 
in the forensic context and highlights that the number of informative tDMSs in the final trace DNA 
analysis is crucial, as some candidate markers identified in reference DNA were shown not 
informative in the trace DNA due to various, including technical, reasons. Future studies will need 
to address the optimal number of epigenetic markers required for reliable identification of MZ twin 
individuals including statistical considerations. 
 
Keywords 
Monozygotic twins, forensic epigenetics, DNA methylation, Illumina 450K array, quantitative 
PCR, whole blood 
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1. Introduction 
Individual identification of monozygotic (MZ) twins in either criminal or paternity casework has 
always been challenging. Since MZ twins are derived from the same zygote, they share a literally 
identical genomic DNA sequence. Except for very rare cases [1], conventional DNA profiling 
techniques using short tandem repeat (STR) genetic markers typically fail to distinguish between 
individuals within the same MZ twin pair. This inevitably leads to a dead-end in police 
investigation and may result in court decisions of prime suspects being set free, which highlights 
the need for a suitable approach to be applied in such cases.  
There is increasing evidence that MZ twins can demonstrate a very small degree of genetic 
differences, in terms of single nucleotide polymorphisms (SNPs) [2], copy number variations 
(CNVs) [3-5], Y-chromosome satellite DNA [6], and bone-marrow-derived memory B 
lymphocytes DNA sequences [7]. However, these sequence differences are extremely rare and 
difficult to locate. Furthermore, their detection in forensic-type samples might be impractical in 
case that they are seen only in a small portion of cells (mosaicism). Proposed genome-wide 
screening methods, such as ultra-deep whole genome sequencing [2], require DNA of high quality 
and quantity and lead to high costs. 
Contrary to the stable genomic DNA sequences, epigenetic patterns, especially DNA 
methylation, are more dynamic as they are influenced by genetic, environmental and stochastic 
factors, the latter two varying throughout an individual’s life [8, 9]. DNA methylation differences 
between both phenotypically concordant and discordant MZ twins have been studied previously, 
not only to investigate naturally occurring variation in DNA methylation and epigenetic 
heritability [10-14], but also to unravel the impact of epigenetics in development and ageing [15, 
16] as well as disease [17-20]. The observed epigenetic drift within MZ twin pairs can be seen at 
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a genome-wide level [12] and also at specific loci [21, 22], which are most likely linked with gene 
regulation involved in specific phenotypes.  
Although the extent of these differences, and to what degree they are shared by different 
MZ twin pairs, is yet not understood, the potential of using DNA methylation to distinguish 
between MZ twins for forensic purposes has already been recognized [23-28], albeit via limited 
studies. In an initial study, Li et al. tested blood DNA samples of 22 adult MZ twin pairs by using 
the Illumina Infinium Human Methylation 27K BeadChip array that allows for the co-analysis of 
27,578 CpG sites, which revealed significant DNA methylation differences (377 CpG sites, 
methylation difference >0.17) [23]. Applying the criterion of how frequent the observed 
methylation differences were amongst MZ twin pairs, authors sub-selected a total of 92 CpGs, that 
were differentially methylated in all 22 pairs [24]. Furthermore, in another candidate-finding 
approach, Du et al [25] analysed four MZ twin pairs with methylated DNA immunoprecipitation 
(MeDIP) and identified a set of 38 differential methylation regions demonstrating pair-specific 
methylation differences, all of which are located within CpG islands (<500bp long, >55% GC 
content, [29]). The majority of these markers are associated with cell differentiation, proliferation 
and development, but future validation is necessary to reveal whether they can be used for MZ 
twin differentiation in routine forensic practice. 
Using a more targeted approach, forensic researchers have also explored the possibility of 
using differential methylation patterns within satellite DNA, and more specifically within 
interspersed repeats such as LINE-1 [26] and Alu sequences [27]. LINE-1 methylation was 
investigated in both blood and buccal cells from a total of 119 MZ pairs using bisulfite 
pyrosequencing. Authors detected statistically significant tissue differences and were able to 
distinguish only a subset (12.61%) of MZ pairs (n=15 pairs) using this specific region (3 CpG 
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sites) in blood [26]. Also, the detected CpG methylation was significantly correlated with gender 
in blood and with age in buccal cells (p=0.001), highlighting the complexity of epigenetic patterns. 
Lastly, in the study by Stewart et al [27], all 5 MZ twins tested were distinguished by analysing 
Alu methylation in buccal cells (2 fragments, 19 CpG sites). The authors used high-resolution 
melting curve analysis, which can differentiate between fragments having differential methylation 
levels on the basis of different melting temperatures. Limitations of such approach include the low 
resolution (investigation of an entire fragment rather than specific CpG sites), the required large 
sample volume and the questioned applicability in other tissues (such as blood or saliva) [27]. 
In the present study, our aim was to execute epigenetic differentiation of MZ twins under 
the forensic scenario, comprising i) the discovery of candidate markers in reference DNA via 
genome-wide screening, ii) validating selected candidate markers in reference DNA using a 
method suitable for forensic trace analysis, and iii) applying such suitable method for analysing 
the validated markers in trace DNA. To the best of our knowledge, this is the first study addressing 
the differentiation of MZ twins in reference-type samples as well as in forensic-type samples, using 
the combination of genome-wide screening and methylation-specific qPCR for targeted analysis. 
 
2. Materials and Methods 
2.1. Sample collection 
This study was approved by the St Thomas’ Hospital Local Ethics Committee, and all participants 
provided signed informed consent prior to sample collection. In total, 10 pairs of female MZ twins 
from the TwinsUK cohort [30], aged 52-62 years and of European ancestry were included in the 
study. Whole blood was collected in EDTA-treated tubes as reference sample, while a small 
amount of blood (a small drop) was also used to make up small bloodstains on cotton material 
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(~0.4-0.5cm2 stains when dried). Samples were stored at -80oC before proceeding to DNA 
extraction and analysis. The monozygosity of the twins used in the study was confirmed by 
genotyping 15 highly polymorphic STR loci using the AmpFLSTR™ Identifiler™ PCR 
Amplification kit (Thermo Fisher Scientific, USA), which resulted in the same STR profile per 
MZ pair respectively. 
 
2.2. DNA sample preparation 
Total DNA from whole blood, representing reference-type DNA samples, was extracted using the 
DNeasy Blood & Tissue kit (QIAGEN, Germany) according to the manufacturer’s instructions. 
Genomic DNA from the dried bloodstains on cotton, representing trace-type DNA samples, was 
isolated using the QIAamp® DNA Investigator kit (QIAGEN) following the recommended 
protocol for ‘Isolation of total DNA from body fluid stains’. The whole blood stain was used for 
DNA extraction and DNA samples were eluted in 20µl. To maximise DNA yield, samples were 
lysed at 56oC for at least 2 hours and QIAshredder spin columns (QIAGEN) were used to harvest 
lysate remaining in the cotton material. To access the accuracy and linearity of methylation 
quantification, 7 DNA standards of known methylation levels (0, 0.1, 0.25, 0.5, 0.75, 0.9, 1) 
(EpigenDx, USA) were also analysed. All DNA samples were quantified using the Quantifiler® 
Human DNA Quantification kit (Applied Biosystems, USA), according to the manufacturer’s 
instructions. For genome-wide analysis, 750ng of extracted DNA was bisulfite-converted using 
the EZ DNA Methylation™ Kit (ZymoResearch, USA). For qPCR analysis, depending on the 
available DNA quality and/or quantity, 200ng (whole blood), 20ng (bloodstains) and 250ng (DNA 
standards) of DNA were treated using the MethylEdge™ Bisulfite Conversion system (Promega, 
USA). Considering 80% DNA recovery after conversion as suggested by the manufacturer, 
bisulfite DNA samples were diluted down to 1ng/µl. 
8 
 
 
2.3. Genome-wide DNA methylation profiling 
Genome-wide DNA methylation profiles used in this study were generated using the Illumina 
Infinium Human Methylation 450K BeadChip array (Illumina, USA). Intensity images were 
captured by GenomeStudio (2010.3) Methylation module (1.8.5) software. The Illumina 450K 
BeadChip assay allows for quantification of DNA methylation levels at 485,512 CpG 
dinucleotides. For each CpG site, a beta value was estimated, ranging from 0, representing 
completely unmethylated, to 1, representing completely methylated sites. The beta value is 
interpreted as average methylation in a particular site taking into account the collection of cells 
that form each sample. The Human Methylation 450K BeadChip array contains two types of beads 
associated with the two different chemical assays, Infinium I and II, which can potentially cause 
bias in probe design [31]. DNA methylation probes that mapped to multiple locations to the 
reference sequence (with exact sequence match and within up to two base pair mismatches)  and 
probes that contain a non-rare polymorphism in the CG site, minor allele frequency (MAF)>0.1 in 
European population from 1,000 genomes, were removed. We only considered autosomal probes 
in the analysis. In total, we restricted our downstream analyses to 438,756 probes. Due to the 
limited and subtle DNA methylation differences expected within each MZ pair (unlike a healthy 
versus diseased tissue), we applied appropriate normalisation approaches to reduce technical 
variability and aiming to improve statistical power. We performed two types of normalisation of 
the 450K array results, subset-quantile normalisation (SWAN) [32] and functional normalisation 
(FUNNORM) [33], both implemented in Bioconductor package Minfi [34]. SWAN performs 
within-array and between-array normalisation to correct for possible technical biases introduced 
by the use of two assay types (Infinium I and II) in the array with different chemistries. In addition, 
functional normalisation is intended to eliminate other non-biological variation known as batch 
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effects. In the normalised datasets, the correlation between MZ twins for each MZ twin pair was 
calculated using Pearson’s correlation across all CpG sites.  
 
2.4. Selection of candidate tDMSs 
Genome-wide data normalised by both the FUNNORM and SWAN methods were used to select 
potential tDMSs for each MZ twin pair. Firstly, the absolute methylation difference for each CpG 
site within each MZ twin pair was calculated in both datasets. FUNNORM methylation differences 
were categorised by applying different thresholds of absolute differences between MZ twins: 0.05, 
0.10 and 0.3. Only the CpG sites demonstrating >0.3 difference were considered for further 
analysis; this threshold was chosen to account for the microarray and processing methods’ 
potential capacity to accurately and reproducibly quantify DNA methylation levels. Only 
candidate tDMSs also confirmed in the SWAN approach by sharing the same level of methylation 
difference (>0.3) were then considered further. For each pair the 3 tDMSs that showed the largest 
differences were chosen for validation [Table S1]. Moreover, for one MZ twin pair, an extra 12 
tDMSs were also selected for validation. Due to an overlap in CpG-sites identified as tDMSs in 
more than one MZ pair, a total of 34 tDMSs were selected for validation. 
 
2.5. Design of methylation-specific PCR approach 
Selected array-derived candidate tDMSs were validated in the same reference DNA used for array 
analysis by means of qPCR. The developed method is a SYBR green-based PCR assay for the dual 
analysis of DNA methylation and CpG methylation density of the entire fragment. The protocol is 
based on previous studies [35, 36] but has been adjusted for more targeted CpG-specific analysis 
suitable for the analysis of forensic-type samples, typically of low DNA quantity and/or quality. 
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The method uses two rounds of PCR amplification; firstly, an end-point, bisulfite-specific PCR 
amplifying the genomic region containing the CpG site of interest, followed by two qPCR 
reactions, one targeting the specific methylated site using methylation-specific primers and a 
second nested one using methylation-independent primers [Figure 1]. The first step of the end-
point bisulfite-specific PCR also has the potential to be multiplexed to enable the simultaneous 
amplification of many target CpG sites and therefore, to increase sensitivity, which can be essential 
when analysing forensic casework samples. Moreover, the use of SYBR green dye allows for 
introducing a melting curve analysis step of the final target amplicons and the determination of the 
methylation density of all CpG sites included in the target sequence. The same qPCR approach 
was used for blood trace DNA methylation profiling. A flow diagram of the entire process with 
the amounts of sample to be used in each step can be found in Figure S1. 
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Figure 1. Methodological approach used for tDMS validation and final trace analysis 
(A) Schematic representation of the developed method from DNA extraction to methylation-
specific qPCR, (B) amplification curves (log(RFU) vs. PCR cycles) and (C) melting peak analysis 
(-d(RFU)/dT vs. temperature) of both low- and highly-methylated DNA standards using a 
methylation-specific primer. 
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The chromosomal location of the selected tDMSs was confirmed using the online 
Ensemble genome browser (human GRCh37/hg19 genome). Primers were designed using the 
online-tool BiSearch [37], specifically intended for methylation analysis. As explained above, for 
each assay four primers were designed, including an external forward primer (EXT-F1), an 
external reverse primer (EXT-R1) and, depending on the assay, a nested forward or reverse primer 
(NES-F2 or NES-R2) as well as a nested methylation-specific reverse or forward primer (NES-
RM or NES-FM). Where possible, the external primers were designed so that they contain no CpG 
site to ensure methylation-independent amplification of the DNA template. To ensure similar 
amplification efficiencies between the two qPCR reactions (methylation-independent and 
methylation-specific), which further facilitates the quantification analysis, only one nested non-
discriminatory primer was used, which was designed so it is ‘shifted’ by as few bps as possible (2-
3bp) from the position of the corresponding methylation-specific primer. Furthermore, it has been 
previously proposed that the presence of a locked nucleic acid (LNA) at the 3’-most end of the 
methylation-specific primer enhances primer binding and allows for efficient discrimination 
between the sequences corresponding to the two methylation states [38]; therefore, LNA-
containing methylation-specific primers were used in this study. The designed assays together with 
the primer sequences can be found in Supplementary Table S2. 
 
2.6. End-point PCR amplification of bisulfite-treated DNA 
During the first end-point PCR step, 1ng of bisulfite-treated DNA was amplified using the 
designed bisulfite-specific primers [Table S2]. For each PCR assay, the primer annealing 
temperature, primer and MgCl2 concentration were optimised; however, one out of 34 PCR assays 
(cg09738481) failed to pass this optimisation step resulting in no or multiple PCR signal and was, 
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therefore, excluded from further analysis. All remaining assays were amplified either using the 
ZymoTaq™ Premix (ZymoResearch) or the QIAGEN Multiplex PCR kit (QIAGEN), as specified 
in Table S2. For each reaction, 6.5µl of 2X ZymoTaq Premix or 2X QIAGEN Multiplex PCR 
Master mix, 1µl of 4X PCR primer mix (final concentration of 0.3µM for each primer), 1µl of 
25mM MgCl2 (only for the ZymoTaq
™ reactions for a final concentration of 3.67mM as the buffer 
already contains 1.75 mM MgCl2), 1µl of bisulfite DNA template (1ng) and 3.5µl (or 4.5µl for the 
QIAGEN reactions) of nuclease-free water, for a total reaction volume of 13µl. The thermocycling 
program used was: 95oC for 10 (ZymoTaq™) or 15 (QIAGEN) minutes, followed by 32 cycles of 
94oC for 30 seconds, Ta for 35 seconds, 72
oC for 35 seconds, and a final extension step of 72oC 
for 7 minutes. Ta is specified in Table S2. Following amplification, the amplicon quality was 
assessed on a 2% agarose gel. Depending on the PCR efficiency, PCR products were diluted 400-
4200 times [Table S2]. All samples including DNA standards, reference samples and bloodstains 
were analysed in duplicate. 
 
2.7. Quantitative PCR (qPCR) assay coupled with melting curve analysis 
During the second real-time qPCR step, 1µl of diluted PCR product was amplified using the 
designed methylation-independent and -specific primers [Table S2]. For each methylation-specific 
qPCR, the primer annealing temperature was also optimised using a temperature gradient. Five 
qPCR assays (cg23066587, cg08299859, cg14754187, cg24719020 and cg26695881) failed to 
pass this second optimisation step resulting in very low CT (PCR cycle number required to reach 
the threshold) and were, therefore, excluded from further analysis. All qPCR reactions were 
performed using SsoAdvanced™ Universal SYBR® Green Supermix (BIO-RAD, USA) on a 
CFX384 Touch™ Real-Time PCR Detection system (BIO-RAD). For each reaction, 5µl of 2X Sso 
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Advanced universal SYBR® Green supermix, 1µl of 2X PCR primer mix (final concentration of 
0.2µM for each primer), 1µl of diluted PCR product and 3µl of nuclease-free water, for total 10µl. 
The thermocycling program used was: 98oC for 3 minutes, followed by 40 cycles of 95oC for 15 
seconds, Ta for 35 seconds and 60
oC for 35 seconds. Ta is specified in Table S2. Following 
amplification, a melt-curve analysis was performed by introducing one cycle of dissociation step 
from 65oC to 95oC (0.5 oC increment, 2 sec/step). All samples were analysed in duplicate, 
corresponding to a total of four replicates for each sample. 
 
2.8. qPCR data analysis   
The difference of CT between the two qPCR reactions (∆CT) was calculated for each sample. As a 
first quality control step, samples that showed a ∆CT outside the range ‘mean ± standard deviation 
∆CT’ for each assay were excluded from analysis. This is to account for random, sub-optimal 
amplification. Raw fluorescent values obtained by qPCR were then analysed using the LinRegPCR 
software [39]. The principle of LinRegPCR software is based on a sample-independent analysis 
that starts with a baseline correction, followed by the calculation of a window-of-linearity and both 
the individual PCR efficiency per sample and mean PCR efficiency per amplicon. A baseline 
fluorescence correction per sample was first performed by plotting the Log(fluorescence) versus 
the cycle number in a linear regression approach. An accurate baseline estimation is key for the 
correct estimation of individual PCR efficiencies. When the baseline-to-plateau distance is too 
short, the baseline fluorescence correction for a sample can fail, indicating that the qPCR 
conditions should be optimised. Furthermore, the built-in iterative algorithm then detects the range 
of PCR cycles that the sample undergoes linear amplification (highest R2 value) during the 
exponential phase and uses this subset of data points to calculate the so-called Window-of-
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Linearity. The individual PCR efficiency per sample in this linear regression approach is defined 
as fold increase per cycle and is calculated as Eff = 10slope. PCR efficiencies are given values 
ranging from 1 to 2, where 2 represents a perfect doubling of the amplicon’s concentration in each 
cycle. Samples with PCR efficiency values lower than 1.5 were excluded from analysis. This type 
of analysis does not use the assumption that PCR efficiency is the same in all samples, but accounts 
for potential effects of individual PCR reaction parameters such as PCR inhibitors. This 
observation was confirmed in this study since many different amplicons and primer sets were 
analysed. This analysis leads to a value of starting DNA material per sample (N0) using the 
equation ‘baseline÷(Eff^CT)’, expressed in arbitrary fluorescence units. N0 values obtained by the 
methylation-specific qPCR reactions were normalised against the methylation-independent qPCR 
reactions to account for differences in PCR efficiency, initial PCR product template applied in the 
qPCR and pipetting errors. N0 values obtained by the DNA methylation standards were used to 
create a calibration curve per assay. Methylation ratios of MZ twin DNA samples were 
subsequently calculated using the resulting equations [an example can be found in Supplementary 
Figure S2]. Lastly, the average temperature of melting peaks of all qPCR replicates was calculated. 
 
3. Results & Discussion 
3.1. Genome-wide DNA methylation patterns of MZ twin reference DNA 
We first explored the correlation between MZ twins in blood DNA considering all CpG sites in 
the final genome-wide microarray dataset considered for downstream analysis. While the 
employed Illumina 450K platform has previously shown high reproducibility [24, 40], beta values 
(methylation ratio) underwent two different normalisation approaches to assess technical bias. 
Using functional normalisation, the average correlation across all CpG sites within a MZ twin-
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pair, considering all MZ twin pairs, was 0.9967 (range 0.996 to 0.998). Similar estimates were 
observed with an alternative normalization approach SWAN (data not shown). An example 
genome-wide DNA methylation profile for one MZ twin pair is shown in Figure 2A.The observed 
high correlation between MZ twins within pairs is in line with previous genome-wide estimate 
from MZ twins [24, 28]. The small DNA methylation differences between MZ twins within pairs 
may be attributed in part to stochastic processes and MZ discordance for environmental exposures, 
phenotypes, and diseases leading to epigenetic footprints. The focus of the present study was to 
explore the value of these epigenetic differences to differentiate MZ twins within pairs.  
 
3.2. Identification of candidate tDMSs in reference-type DNA 
To identify candidate tDMSs per MZ twin pair, we calculated the within-pair absolute difference 
in DNA methylation levels for all 438,756 CpG sites tested on the Illumina 450K array, and 
assessed the number of tDMSs with blood methylation differences larger than 0.05, 0.10 and 0.3, 
respectively (beta values) [Figure 3A]. The results were similar across both FUNNORM and 
SWAN normalisation approaches. Considering CpG sites that surpassed the difference threshold 
in both normalisation methodologies, and averaging over 10 tested MZ twin pairs, the following 
proportions of tDMSs were observed (average ± standard deviation): 7.94% (34,840 ± 8,413), 
1.27% (5,586 ± 3,230) and 0.013% (56 ± 32), for a methylation level difference of >0.05, >0.10 
and >0.3, respectively [example in Figure 2B]. These findings suggest that tDMSs within MZ twin 
pairs are subtle, yet substantial. Furthermore, the distribution of the detected large differences 
(>0.3) is shown in Figure 3B; depending on the twin pair there are 1 (pair 1) to 22 (pair 7) candidate 
tDMSs at 0.7 threshold of twin-to-twin methylation difference. 
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Figure 2. Genome-wide DNA methylation and tDMS analysis in an example MZ twin pair 
(A) Genome-wide DNA methylation profiles from microarray analysis, and (B) selected tDMSs 
using FUNNORM normalisation. 
(A) 
(B) 
r=0.996 
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Figure 3. Array-derived candidate tDMSs in reference DNA of 10 MZ twin pairs  
(A) Number of markers in both normalisation methods at different methylation difference cutoffs, 
(B) 3D surface plot showing the distribution of the number of tDMSs demonstrating large 
differences (>0.3) by both normalisation approaches. 
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For further analysis, we focused on the common tDMSs that overlap between both 
normalisation methods using the methylation difference threshold of 0.3. As a result, the number 
of array-derived candidate tDMSs ranged between 19 and 111 depending on the investigated MZ 
twin pair [Figure S3A]. The majority of these differences are pair-specific, although there are some 
tDMSs that are shared among twin pairs. At the 0.3 cutoff and considering all twin pairs, we 
detected a total of 433 tDMSs, from which 358 were unique and pair-specific, while the remaining 
75 (17.31%) are shared among two to five MZ pairs. Particularly, 9% are shared among two pairs, 
while 4.39%, 3.46% and 0.46% are shared among three, four and five pairs, respectively.  
Moreover, the majority of these tDMSs (68%), found equally on both the forward and 
reverse DNA strands, are located in or near genes [Figure S3B], with approximately half located 
in the gene body (47%) and a proportion in other functional regions such as the 5’ untranslated 
region (5’-UTR) (7%) [Figure S3C]. Furthermore, according to Illumina, 19% of the identified 
tDMSs at the 0.3 threshold are located in enhancers, indicating their potential role in regulating 
gene expression. Lastly, the probes used in this array have been designed to specifically target 
CpG islands (CGI) (<500bp, GC content>55%, [29]), CGI shores (up to 2kb from CGI), CGI 
shelves (between 2-4kb from CGI) and non-CpG island regions (>4kb from CGI). We investigated 
whether tDMSs appear more often in specific chromosomal regions according to CpG content, 
and observed that 27% of tDMSs are annotated to fall in CGIs, 25% in CGI shores, 6% in CGI 
shelves and 42% are non-CGI probes [Figure S3D]. At this cutoff, it seems that CGI probes are 
highly represented, which has been previously supported by similar studies [25, 28]. 
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3.3. Technical validation of array-derived candidate tDMSs in reference-type DNA 
As described in the methods, for each MZ twin pair the top 3 tDMSs identified by both functional 
and subset-quantile normalisation were selected for technical validation [Table S1] by employing 
CpG-specific qPCR approach in the same reference-type DNA samples previously used for 
microarray analysis. Since some of these top tDMSs (n=6, cg25949955, cg08240074, cg05905030, 
cg09007841, cg01585094, cg10617763) overlapped across MZ twin pairs (up to 3 pairs), the final 
set of candidate tDMSs involved in the validation testing comprised of 22 CpGs in total. The 
majority of selected tDMSs (12 out of 22) were located in genes, specifically ISM1, SLC12A7, 
NXN, MYH7, RPTOR, GPR125, PLK1, SLIT1, ANGPT1, MLF2, RNF44 and CPNE7. The 
associated genes have been previously reported to be involved in biological processes such as cell 
growth and differentiation, metabolism, insulin recycling, vascular and neural development, and 
have also been associated with common health conditions like cancer, tumor angiogenesis, 
cardiomyopathy and myeloid leukemia. The normalised methylation levels at these top tDMSs as 
detected in the array are presented in Table S3. In all cases, the expected methylation differences 
within a MZ twin pair were substantial, as these candidate CpGs seem to be either un-methylated 
or fully methylated as suggested by the array data.  
The importance of technical validation of the methylation results obtained from genome-
wide DNA methylation screening approaches, such as microarray analysis used here, by using 
more quantitative, locus-specific assays has been highlighted before [41], but has not yet been 
adopted in most of the previous forensically motivated studies addressing MZ twin differentiation. 
Validating the candidate tDMSs is needed not only to assess the quality and accuracy of the 
obtained data, but also to determine whether the specific detected differences observed between 
MZ twins in the array analysis are reproducible across technologies. This is especially important 
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in forensic epigenetic applications where screening methods to identify candidate markers such as 
microarrays are not suitable for trace DNA analysis due to DNA quality and quantity restrictions 
in forensic material. Despite the use of two normalisation methods on the microarray data, 
technical validation in the same DNA used for microarray analysis is still required to assess 
reproducibility of the findings. For this purpose, and for subsequent trace DNA analysis, we 
developed a CpG-specific qPCR approach, as outlined in the methods section. DNA methylation 
data were derived by applying a standard curve from known DNA methylation standards for each 
assay; an example of this analysis can be found in Figure S2. Overall, the DNA methylation results 
obtained from this technical validation step in the same reference-type DNA samples used for 
array analysis are presented in Table 1. 
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Taking into account all candidate tDMSs, using our qPCR approach we successfully 
detected at least 0.1 twin-to-twin difference for 19 tDMSs (67.85%), while 9 tDMSs (32.15%) 
gave lower (<0.1) methylation differences. As shown in Table 1, using the qPCR approach in MZ 
twin’s reference DNA samples did not generally show non-methylation/fully methylation profiles 
as previously observed in the array analysis, but there were some exceptions, specifically the top 
3rd tDMS in twin pair 3 (cg04359702) with 0.705 qPCR difference and top 2nd tDMS in twin pair 
5 (cg27326062) with 0.715 qPCR methylation difference. There were also some cases where one 
twin showed a very low or high methylation profile as expected from array data, while the other 
twin demonstrated intermediate methylation, not expected from array data. For example, for top 
1st tDMS in twin pair 4 (cg26886231), twin 4A had no methylation while twin 4B had a value of 
0.586. Nevertheless, and most importantly, the methylation differences kept the same direction 
across the two methods for 22 out of the 28 tDMSs, meaning twin A showing higher methylation 
than twin B, or vice versa.  
Our difficulty to qPCR-replicate the exact array-based methylation differences at most of 
the tDMSs could be partly explained by potential technical batch effects in the Illumina 450K 
array, such as potential probe bias, potential variability in M vs. U bead intensity signal differences, 
albeit our normalization approach tried to minimise those, and/or variation introduced by 
incomplete bisulfite conversion. DNA methylation detection inaccuracies due to probe bias have 
also been mentioned before [31] and could be explained either by the probe mapping to multiple 
genomic locations (which we removed in our study) or by a probe sequence harboring a SNP site 
commonly present within a sample and hence, influencing its ability to hybridise DNA. 
Nevertheless, studies on the impact of SNPs on the probe sequences show that, unless the SNP is 
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on the target CpG site, they do not significantly affect hybridization [42]. On the other hand, many 
probes contain additional CpGs, which may introduce another base pair mismatch depending on 
their methylation status, hence affect probe binding and methylation detection (especially 
regarding Infinium design type I probes). For example, at cg01585094 we observed discrepancies 
for both twin pair 10 (top 3rd tDMS) and twin pair 7 (top 2nd tDMS), which could be explained 
by the presence of four additional CpGs on the probe sequence. A discrepancy was also observed 
for top 1st tDMS in twin pair 8 (cg00922825), where both twins showed a very low methylation 
profile with the qPCR method (0.19). Here, an explanation could lay behind the fact that this 
particular site for twin 8B had not been converted during bisulfite treatment in the genome-wide 
experiment (hence 0.97 methylation) [Table S3], resulting in a false-positive tDMS identification. 
Lastly, we cannot exclude inter-methodological differences between the probe-based array 
experiment and the PCR-based targeted approach, as each uses a different chemistry. For example, 
potential occurring amplification bias together with possible errors during PCR product dilution 
in our targeted experiments cannot be excluded, highlighting the need to assess the performance 
of the developed qPCR assays before moving to the forensic-type samples. For extra validation, 
we also sequenced our PCR products with a standard Sanger sequencing protocol, which resulted 
in similar DNA methylation values with the ones obtained by qPCR for all tested tDMSs (data not 
shown). We understand that we do place a lot of trust on quantifying exact methylation values 
between the methods, which might not be possible in the end (except for perhaps in the case of 
ultra-deep bisulfite sequencing, but even then there could be issues with the surrounding 
sequence). Looking at the raw methylation data across microarray vs qPCR values [Tables 1 and 
S3], we observed ‘same’ methylation levels in only ~25%. Hence, while from a forensic standpoint 
we would like to have methylation values and differences as precise as possible when comparing 
24 
 
these datasets obtained by two methods, we might need to re-evaluate our approach of calculating 
validation success rates in future studies. 
 
3.4. Analysis of validated tDMSs in trace-type DNA 
Despite the observed discrepancies, we detected substantial differences between twin individuals 
within each MZ twin pair also with our qPCR approach. For twin pairs 1, 4, 5, 6 and 9, substantial 
methylation twin-to-twin differences at the 0.1 level were qPCR-verified for all array-derived 
candidate tDMSs tested [Table 1], while for pair 7 only one candidate tDMS was validated at the 
0.1 level, and for pairs 8 and 10, we were unable to verify at the 0.1 level any of the candidate 
tDMSs tested. Moving to the next step in the forensic scenario of epigenetic MZ twin 
differentiation, we qPCR-tested the technically validated tDMAs with >0.1 methylation 
differences (19 out of 28 tDMSs, in 8 out of 10 MZ twin pairs) in the trace-type DNA derived 
from small blood stains produced from the same blood of which the reference-type DNA were 
obtained [Figure 4]. Taking into account all replicates analysed from the reference DNA, we 
estimated the standard error of each CpG assay, which ranged between 0.012 and 0.102, suggesting 
that the used qPCR method was both reproducible and sufficiently accurate to confidently detect 
10% methylation differences. These data serve as prerequisite to use tDMSs with at least 0.1 
methylation differences in the qPCR analysis of the trace DNA. Looking at all 38 tDMS 
comparisons [Figure 4] for 13 (34.2%) trace DNA methylation was within the expected range of 
standard error taking into account observed technical variation (average deviation from reference 
samples 0.014), 15 (39.5%) showed a considerably lower methylation in trace DNA (average 
deviation of -0.243) while the remaining 10 (26.3%) showed higher methylation (average 
deviation of 0.321) compared to the reference DNA qPCR results. 
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Figure 4. qPCR-based methylation levels of validated tDMSs in both reference-type and 
trace-type DNA for the 8 MZ pairs for which any of the three top candidate tDMS tested was 
validated at the 0.1 level of methylation difference in the reference DNA 
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We cannot exclude that different sample preparation in bloodstains due to limited 
availability (lower DNA amounts treated in bisulfite conversion) may not have introduced possible 
differences across reference and trace DNA. In some cases, such as for the top 3rd tDMS in twin 
pair 5 (cg05905030) [Figure 4E] the difference can be quite extreme (0.07 in reference A and 0.76 
in stain A, while 0.32 in reference B and fully methylated -1- in stain B). Some of the discrepancies 
between reference and trace-type DNA of the same individuals are likely explained by bisulfite 
conversion issues, as this treatment procedure is known to be sensitive to the starting quantity of 
DNA and, according to the manufacturer, does not work optimally with starting amounts of 
<200ng. While for the reference DNA 200ng of DNA was treated with bisulfite (within the optimal 
DNA input range of the kit), for the trace DNA 20ng of DNA was used due to the low quantity of 
blood DNA available from the traces. The less efficient the bisulfite conversion is, the higher the 
observed methylation values can be due to ‘false positive’ methylation. Furthermore, due to the 
limited starting DNA availability in bloodstains and as seen previously in other studies [43], we 
cannot exclude potential amplification bias towards the unmethylated allele during the first end-
point PCR, which could partly explain the detected lower methylation in trace DNA. Also, we 
cannot exclude that due to the minute stain the overall cell composition could be slightly different 
compared to the whole blood liquid sample contributing towards a very small part of the observed 
discrepancies. While 20ng of DNA could be considered adequate for good sampling 
(corresponding to ~3,000 cells), cell type-specific DNA methylation patterns in whole blood have 
been observed [44, 45]. 
Out of the 19 twin-to-twin comparisons, 13 tDMSs (68.4%) still resulted in a twin-to-twin 
difference of >0.1, while the remaining 6 tDMSs (31.6%) resulted in low (<0.1) methylation 
differences. On average, the deviation between the detected DNA methylation differences in 
27 
 
reference and stain sets was 0.139, which can be partly explained by the expected technical 
variation. However, there were certain tDMSs that failed to show significant DNA methylation 
difference in trace DNA, given the expectations from the validated reference DNA. For example, 
top 1st tDMS in twin pair 5 (cg13291296) [Figure 4E] and top 3rd tDMS in twin pair 9 
(cg10617763) [Figure 4H] resulted in no difference in the trace DNA of twin A and B, respectively. 
This makes the selected tDMSs non-informative for MZ twin differentiation in the final trace 
analysis. More importantly, however, for top 3rd tDMS in twin pair 2 (cg08240074) [Figure 4B] 
and top 1st tDMS in twin pair 7 (cg09007841) [Figure 4G] methylation differences in the trace 
DNA were reversed relative to reference DNA. Such scenario would, therefore, lead to false 
positive identification in a practical application when only considering such markers. 
 
3.5. Analysis of additional tDMSs in one twin pair 
From our observation that some validated tDMSs showed discrepant methylation results in trace 
DNA compared to reference DNA leading to reduced marker sets available for MZ twin 
differentiation from trace material - particularly evident in the case of twin pair 7 of this study - 
we investigated an increased number of candidate tDMSs for this pair. For this purpose, we 
selected 8 additional twin pair-specific candidate tDMSs from the array data that met the cut-off 
criterion of >0.3 twin-to-twin DNA methylation difference. In an attempt to improve our marker 
selection strategy, these markers did not necessarily demonstrate a binary methylation profile 
(0.35-0.74 methylation difference) in the array data, which could potentially be caused by 
complete analysis failure in one of the two twins within a pair, for instance due to incomplete 
bisulfite conversion prior to array analysis. In the qPCR validation analysis using the same 
reference DNA as used for array analysis, 7 out of 8 tDMSs (87.5%) showed >0.1 DNA 
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methylation difference (ranging from 0.164 to 0.950), and were consequently analysed in the trace 
DNA [Figure 5]. Overall, the concordance between reference and bloodstain methylation within 
each twin individual was high (average deviation of 0.08, with cg27370028 in twin 7A the only 
exception as the bloodstain resulted in a higher methylation, 0.304). Detected methylation 
differences between reference-type and trace-type DNA were also concordant for most tDMSs 
(except for cg27370028) [Figure 5]. As partly seen and explained before, trace DNA showed 
generally lower methylation levels than reference-type DNA also concerning these markers. 
Although more data are needed to underline this conclusion, it seems that selecting candidate 
tDMSs showing intermediate methylation differences between twins within a pair from the array 
data might be as informative as the ones showing maximal differences. We also observed that this 
selection approach avoiding only markers with on/off methylation in the array data could actually 
increase the chance of avoiding markers that turn out to be non-informative in the final trace 
analysis, which should be considered and further explored in future studies. 
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Figure 5. qPCR results of additional array-derived validated tDMSs in MZ twin pair 7 in 
both reference and trace DNA following an updated candidate marker selection strategy 
 
3.6. Complementary high-resolution melting curve analysis 
High-resolution melting curve analysis enables for the separation of fragments with different 
sequences due to their difference in CG-content and melting temperature. In the present study, we 
aimed to combine our proposed quantitative CpG-specific qPCR with a qualitative fragment-
specific melting analysis, so that we can assess the methylation status of our entire PCR amplicon 
including all CpGs covered. Considering that adjacent CpGs are likely to share similar methylation 
levels [46], we hypothesized that substantial DNA methylation differences could potentially be 
evident also around the genomic area of our candidate tDMSs and aimed to explore how useful 
this approach might be for epigenetic MZ twin differentiation. Interestingly, considering all tDMSs 
analysed so far, we detected inter-twin melting temperature differences in 27 out of the 36 potential 
twin-differentiating PCR products (75%) in the reference DNA. Two examples are presented in 
Figure 6. Of course, we cannot exclude the possibility of existing fragment methylation differences 
between MZ twin pairs in the rest 9 fragments that, nevertheless, cancel each other out at the total 
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fragment melting temperature. However, out of these 27 PCR products we could only replicate 13 
(48.1%) in the corresponding trace DNA, which corresponds to the detected lower DNA 
methylation differences of our specific CpGs in bloodstains. Taking into account the number of 
CpGs included in each specific fragment, we calculated that these melting temperature differences 
translate to 0.01-0.53 fragment methylation differences. However, the advantage of including such 
melting curve analysis can be seen in top 1st tDMS in twin pair 5 (cg13291296), top 2nd tDMS in 
twin pair 6 (cg09007841) and top 3rd tDMS in twin pair 9 (cg10617763), that, despite their small 
methylation differences detected in bloodstains [Figure 5E, 5F and 5H], they show a 0.40, 0.10 
and 0.16 methylation difference when the entire fragments are considered. Moreover, the true 
complementary nature of combining targeted techniques can be seen in four tDMSs that resulted 
in no substantial differences when only qPCR was employed, but gave substantial fragment 
methylation differences using high-resolution melting curves (two tDMSs in the ‘challenging’ MZ 
twin pair 8: top 1st tDMSs - cg00922825 and top 3rd tDMSs  cg10617763). Therefore, we propose 
that, whenever possible, the entire surrounding region of candidate tDMSs is co-analysed. 
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Figure 6. Examples of high-resolution melting curve analysis in MZ twin pair 7 reference 
DNA for two assays 
  
(A) Fragment surrounding cg27370028 (10 CpGs, 154 bp) 
Twin 7B – 76.5ºC Twin 7A – 76.0ºC 
(B) Fragment surrounding cg24371114 (11 CpGs, 257 bp) 
Twin 7A - 76.5ºC Twin 7B – 77.2ºC 
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4. Final discussion and future work 
Differentiating between MZ twins for forensic purposes is currently impossible using standard 
forensic use of DNA via STR profiling. On the other hand, epigenetics and especially DNA 
methylation profiling has been recently proposed as a suitable approach to overcome this 
challenge. Hence, the aim of this project was to test the complete scenario of future epigenetic MZ 
twin differentiation in forensic casework, including the analysis of both reference- and trace-type 
DNA. During marker discovery, our genome-wide experiment revealed numerous potentially 
useful candidate tDMSs per MZ twin pair. We understand that on a biological level this number 
can be influenced by various factors, such as the age and gender of twins, the investigated tissue, 
potential disease state or phenotype discordance as well as the degree of unique/shared 
environment between twin individuals within the same pair, and thus, is likely to largely vary 
between different pairs. Moreover, on a technical level the adopted normalisation strategy can also 
influence the resulting number of candidate markers, as seen here by using two different methods. 
In this study we focused our analysis in blood by testing reference-type whole blood 
samples and trace-type bloodstains. DNA methylation is known to be tissue-specific [47], 
therefore it is important to address the limitation of comparing between different tissues by 
ensuring that both reference and trace samples originate from the same tissue. In case of blood or 
saliva stains this might be possible, however we understand that in certain cases it might be 
unlikely that legal authorities will be able to allow for collection of the tissue of interest (such as 
semen in sexual assault cases). Using a reference sample from a different tissue may not be entirely 
suitable for comparison to a trace sample from a different tissue origin, unless there are CpG sites 
that show twin-differentiating DNA methylation across tissues. Nevertheless, this has yet to be 
determined. 
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Although numerous candidate tDMSs were obtained from microarray analysis in blood, 
only a portion (just over two thirds) of the selected candidate markers, and subsequently, another 
two thirds of the validated markers, resulted in >0.1 difference in reference- and trace-type DNA, 
respectively. We believe that these findings can be partly explained by technical variation, method-
to-method discrepancies and perhaps by the marker selection approach. While differences in the 
sample analysis (in terms of extraction and bisulfite treatment) between the reference- and trace-
type DNA samples can also play a role, DNA from bloodstains seemed to generally provide lower 
methylation. While bloodstains were collected at the same time point with reference samples, they 
were subsequently stored at -80oC until qPCR analysis (span of several months), we are uncertain 
whether this storage could have any significant effect. We suggest that future studies take into 
account these possibilities of ‘losing’ potentially informative markers throughout the proposed 
step-wise analysis.  
One factor not considered and tested with our study design, which could lead to further 
complications in practical forensic epigenetic applications, is the potential in-vivo longitudinal 
instability of tDMSs identified in reference DNA via genome-wide analysis, as trace and reference 
samples are typically not collected at the same time point (as done in our study for reasons of 
simplification). If a tDMS selected from the reference DNA screening analysis changes its 
methylation status during the time between sampling of reference DNA and placement of trace 
DNA, this would make such tDMSs non-informative for twin differentiation from trace DNA. In 
an recent attempt to study the stability of CpG methylation overtime Zhang et al [28] analysed 
blood DNA samples obtained from 10 MZ pairs together with 8 individuals collected at four time 
points over 9 months using the Illumina Infinium Human Methylation 450K BeadChip array. The 
authors found a subset of CpG sites (located on CpG islands) with changing methylation over this 
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short time period, but detected no significant overall epigenetic drift within the same individual 
[28].  
Another aim of our manuscript was to provide a forensically suitable alternative for 
accurate and reproducible DNA methylation detection that could not only provide single CpG-
resolution, but is also cheap and allows for high-throughput. Although we understand that the 
nested qPCR design we developed might introduce extra variation in DNA methylation detection 
accuracy, its set-up will eventually allow for the construction of a twin-specific multiplex end-
point PCR, which can increase the overall sensitivity and allow for the analysis of very low 
quantity/quality samples. Initial validation showed that 50 pg of starting DNA material were 
sufficient for complete and accurate methylation profiles (data not shown). Nevertheless, further 
validation including extensive reproducibility and repeatability testing is still required to fully 
assess and explain the variability of detected DNA methylation, as observed between whole blood 
reference samples and minute bloodstains, which is expected to be tDMS-dependent. One can also 
consider applying potentially more specific and sensitive probe-based qPCR approaches, such as 
MethyLight [48], which can also be useful from a forensic standpoint.  
Taking into account the observed variation and the potential effect of various technical and 
biological factors, and as indicated by our data from one example MZ pair, future forensic twin 
differentiation might require the analysis of a large number of twin-specific markers to allow 
individual identification of MZ twins from epigenetic data. However, analysing a large number of 
CpGs (at hundreds or thousands level) via qPCR or other similar targeted approaches might appear 
not practical. On the other hand, genome-wide technologies, such as microarray analysis or whole 
genome bisulfite sequencing, are not practical either as they require DNA qualities and quantities 
typically not available from crime scene materials. Technologies, such as targeted bisulfite 
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sequencing using massively parallel sequencing platforms expectedly allow for the parallel 
analysis of more CpGs (at least 16-24 CpG loci, [49, 50]) from low-quality and -quantity DNA 
compared to what is possible with other targeted approaches, such as qPCR and pyrosequencing. 
However, future work is still needed to show how many DNA methylation markers can be 
multiplexed with such technologies. Nevertheless, as far as we see it, the ideal approach for 
forensic MZ twin differentiation would use the same highly-sensitive and reliable, non-targeted 
epigenetic screening technology in reference- and trace-type DNA, providing a large number of 
tDMSs for individual identification of MZ twins, which at this moment is not available. 
Future work is also needed to establish from a statistical point of view how many tDMSs 
are required for trustworthy individual identification of MZ twins from crime scene material. 
While the purpose of this study was not to propose a valid statistical approach on how to convey 
the strength of DNA methylation evidence towards reliable MZ identification, we understand that 
this is an important aspect that has not been demonstrated yet. Future studies are needed to 
‘translate’ methylation differences into probabilities of observing such methylation levels under 
two hypotheses (e.g. twin A being the stain donor vs. twin B being the stain donor), which should 
consider the best way to combine methylation data from different CpG sites (their methylation of 
which might not be independent) and how to calculate methylation level frequencies. Blind testing 
to compare the methylation profile of a bloodstain vs. the methylation profiles of the twins’ 
reference samples is expected to reveal how well assignment to the ‘right’ twin can be made and 
how often discrepancies are observed, however this will require an advanced and complex 
statistical approach. 
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Twin pair Twin 
Array-derived candidate tDMSs            
(DNA methylation ratio) 
    
    
top 1§ top 2§ top 3§     
1 
A 0.558 0.158 0.647     
B 0.682 0.298 0.368     
Diff* 0.124 0.140 0.279     
2 
A 0.609 0.365 0.446     
B 0.609 0.111 0.249     
Diff 0.000 0.254 0.197     
3 
A 0.856 0.430 0.000     
B 0.766 0.846 0.705  
 
  
Diff 0.090 0.416 0.705    
4 
A 0.000 0.342 0.122    
B 0.586 0.891 0.598    
Diff 0.586 0.549 0.476    
5 
A 1.000 0.152 0.066    
B 0.715 0.867 0.323    
Diff 0.285 0.715 0.257    
6 
A 0.407 0.762 
N/A 
   
B 0.770 0.566    
Diff 0.363 0.196    
7 
A 0.982 0.073 0.460    
B 0.612 0.080 0.527   
Diff 0.370 0.007 0.067     
8 
A 0.199 1.000 0.833     
B 0.190 1.000 0.882     
Diff 0.009 0.000 0.049     
9 
A 0.689 0.451 0.685     
B 1.000 0.781 0.933     
Diff 0.311 0.330 0.248     
10 
A 
N/A 
0.403 0.075     
B 0.385 0.071     
Diff 0.018 0.004     
         
*Within-pair absolute DNA methylation difference between twin A 
and twin B - Expected >30% 
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DNA methylation levels 
Table 1. Summary of qPCR results of array-derived candidate tDMSs in the same reference-
type DNA used for array analysis for the three top markers per MZ twin pair 
 
